Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication.
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced*; D007006:Hypogonadism / Q000139:chemically induced; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced; D011388:Prolactin / Q000097:blood; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D011388:Prolactin; D018967:Risperidone